Literature DB >> 21420716

Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas.

Michelle D Williams1, Li Zhang, Danielle D Elliott, Nancy D Perrier, Guillermina Lozano, Gary L Clayman, Adel K El-Naggar.   

Abstract

The classification of follicular thyroid neoplasms requires surgical resection for histologic evaluation of malignancy. Because variable clinical behavior exists, genomic expression profiling may lead to the identification of novel markers that facilitate better biologic classification. We performed for the first time gene expression analysis on clinically aggressive and nonaggressive follicular carcinomas (FCs) from patients for whom long-term follow-up data were available. We examined matched fresh-frozen tissue from 15 histopathologically diagnosed follicular carcinomas (7 patients with documented distant metastasis and/or death from disease and 8 patients without recurrence). For categorical comparison, we analyzed 4 follicular adenomas (FAs). The biologic control comprised 11 normal thyroid tissue specimens. High-quality RNA was extracted from the tissues, labeled, and hybridized to an Affymetrix (Santa Clara, CA) oligonucleotide microarray (HG-U133A). With the exceptions of 1 follicular adenoma and 1 follicular carcinoma, unsupervised hierarchical cluster analysis revealed 2 distinct groups--one containing normal thyroid tissue and follicular adenomas and another containing follicular carcinomas. We identified 421 genes that were differentially expressed between histologically normal thyroid tissues and all follicular neoplasms (P < 0.01; fold-change >2), 94 genes that distinguished follicular carcinomas from follicular adenomas (including PBP and CKS2), and 4 genes that distinguished aggressive follicular carcinomas from nonaggressive follicular carcinomas (NID2, TM7SF2, TRIM2, and GLTSCR2). Comparative genomic groupings identified differentially expressed genes that may lead to better classification of follicular thyroid neoplasms. Such genes may be used in future prospective validation studies to establish clinically useful and complementary diagnostic markers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420716      PMCID: PMC3156288          DOI: 10.1016/j.humpath.2010.12.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  A model of molecular interactions on short oligonucleotide microarrays.

Authors:  Li Zhang; Michael F Miles; Kenneth D Aldape
Journal:  Nat Biotechnol       Date:  2003-06-08       Impact factor: 54.908

2.  Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination.

Authors:  Frank Weber; Lei Shen; Micheala A Aldred; Carl D Morrison; Andrea Frilling; Motoyasu Saji; Frank Schuppert; Christoph E Broelsch; Matthew D Ringel; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

3.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.

Authors:  Barbara Jarzab; Malgorzata Wiench; Krzysztof Fujarewicz; Krzysztof Simek; Michal Jarzab; Malgorzata Oczko-Wojciechowska; Jan Wloch; Agnieszka Czarniecka; Ewa Chmielik; Dariusz Lange; Agnieszka Pawlaczek; Sylwia Szpak; Elzbieta Gubala; Andrzej Swierniak
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

Review 5.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

6.  Using gene expression profiling to differentiate benign versus malignant thyroid tumors.

Authors:  Chiara Mazzanti; Martha A Zeiger; Nick G Costouros; Christopher Umbricht; William H Westra; Danelle Smith; Helina Somervell; Generoso Bevilacqua; H Richard Alexander; Steven K Libutti; Nick Costourous
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

7.  Classification of follicular thyroid tumors by molecular signature: results of gene profiling.

Authors:  Catherine B Barden; Katherine W Shister; Baixin Zhu; Gerardo Guiter; David Y Greenblatt; Martha A Zeiger; Thomas J Fahey
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes.

Authors:  Micheala A Aldred; Ying Huang; Sandya Liyanarachchi; Natalia S Pellegata; Oliver Gimm; Sissy Jhiang; Ramana V Davuluri; Albert de la Chapelle; Charis Eng
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

9.  Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.

Authors:  David J Finley; Nimmi Arora; Baixin Zhu; Lisa Gallagher; Thomas J Fahey
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

10.  Identification of borderline thyroid tumors by gene expression array analysis.

Authors:  Nimmi Arora; Theresa Scognamiglio; Carrie C Lubitz; Tracy A Moo; Meredith A Kato; Baixin Zhu; Rasa Zarnegar; Yao-Tseng Chen; Thomas J Fahey
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

View more
  11 in total

1.  CKS2 in human cancers: Clinical roles and current perspectives (Review).

Authors:  Hanyu You; Huayue Lin; Zhongying Zhang
Journal:  Mol Clin Oncol       Date:  2015-02-04

Review 2.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  The loss of Tm7sf gene accelerates skin papilloma formation in mice.

Authors:  I Bellezza; L Gatticchi; R del Sordo; M J Peirce; A Sidoni; R Roberti; A Minelli
Journal:  Sci Rep       Date:  2015-03-25       Impact factor: 4.379

4.  Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours.

Authors:  Bartosz Wojtas; Aleksandra Pfeifer; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Agnieszka Czarniecka; Aleksandra Kukulska; Markus Eszlinger; Thomas Musholt; Tomasz Stokowy; Michal Swierniak; Ewa Stobiecka; Ewa Chmielik; Dagmara Rusinek; Tomasz Tyszkiewicz; Monika Halczok; Steffen Hauptmann; Dariusz Lange; Michal Jarzab; Ralf Paschke; Barbara Jarzab
Journal:  Int J Mol Sci       Date:  2017-06-02       Impact factor: 5.923

5.  PICT-1 is a key nucleolar sensor in DNA damage response signaling that regulates apoptosis through the RPL11-MDM2-p53 pathway.

Authors:  Hongbo Chen; Liqiao Han; Hsiangi Tsai; Zhiwei Wang; Yanping Wu; Yanhong Duo; Wei Cao; Lijun Chen; Zhirong Tan; Ning Xu; Xianzhang Huang; Junhua Zhuang; Laiqiang Huang
Journal:  Oncotarget       Date:  2016-12-13

6.  A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.

Authors:  Stéphanie Durand; Killian Trillet; Arnaud Uguen; Aude Saint-Pierre; Catherine Le Jossic-Corcos; Laurent Corcos
Journal:  BMC Genomics       Date:  2017-09-30       Impact factor: 3.969

7.  TRIM2 downregulation in clear cell renal cell carcinoma affects cell proliferation, migration, and invasion and predicts poor patients' survival.

Authors:  Wen Xiao; Xuegang Wang; Tao Wang; Jinchun Xing
Journal:  Cancer Manag Res       Date:  2018-11-20       Impact factor: 3.989

8.  NOP53 as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer.

Authors:  Aida Orois; Sudheer K Gara; Mireia Mora; Irene Halperin; Sandra Martínez; Rocio Alfayate; Electron Kebebew; Josep Oriola
Journal:  Genes (Basel)       Date:  2019-11-07       Impact factor: 4.096

9.  Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Authors:  Marsha Crochiere; Trinayan Kashyap; Ori Kalid; Sharon Shechter; Boris Klebanov; William Senapedis; Jean-Richard Saint-Martin; Yosef Landesman
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

10.  TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma.

Authors:  Zhaoxian Lin; Xing Lin; Lihuan Zhu; Jianyuan Huang; Yangyun Huang
Journal:  Cancer Cell Int       Date:  2020-06-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.